PSORCON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PSORCON (PSORCON).
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Topical diflorasone diacetate is absorbed percutaneously. The extent of absorption depends on factors such as application site, integrity of skin, and use of occlusive dressings. Hepatic metabolism is likely via the cytochrome P450 system, though specific enzymes are not well documented. |
| Excretion | Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%. |
| Half-life | Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing. |
| Protein binding | Approximately 90–95% bound to plasma proteins, mainly albumin. |
| Volume of Distribution | Not well characterized for topical use; systemic Vd estimated around 0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: Bioavailability is minimal (estimated <1%) through intact skin; increased with occlusive dressings or inflamed skin (up to 5%). |
| Onset of Action | Topical: Onset of clinical effect (e.g., reduction of inflammation) occurs within 1–2 weeks of regular application; no systemic onset data applicable. |
| Duration of Action | Duration of action: 12–24 hours after topical application, supporting twice-daily dosing; clinical note: continuous use beyond 2 weeks should be re-evaluated due to risk of adrenal suppression. |
| Molecular Weight | 494.5 Da |
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in children have not been established; use only if potential benefit outweighs risk. |
| Geriatric use | Use with caution due to increased risk of skin atrophy; apply sparingly to small areas for short durations. |
| 1st trimester | Teratogenic effects have been observed in animal studies; use only if potential benefit justifies risk. Avoid first trimester unless necessary. |
| 2nd trimester | May cause intrauterine growth restriction and adrenal suppression in fetus; monitor fetal growth. Use with caution. |
| 3rd trimester | Risk of neonatal adrenal suppression; avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for PSORCON (PSORCON).
| Placental transfer | Systemic corticosteroids cross placenta; degree varies with potency and dose. Psorcon (diflorasone diacetate) is a high-potency corticosteroid with moderate placental transfer. |
| Breastfeeding | Excreted in breast milk; avoid application to breast area. Use lowest effective dose for shortest duration. Monitor infant for signs of adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to diflorasone diacetate or any componentUntreated bacterial, fungal, or viral skin infectionsTuberculosis of the skinVaricellaHerpes simplex
| Precautions | Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can occur, Pediatric patients may be more susceptible to systemic toxicity, Prolonged use may cause local atrophy, striae, telangiectasias, and purpura, Do not use in the presence of untreated bacterial, fungal, viral, or parasitic infections |
| Food/Dietary | No known food interactions. Avoid alcohol if using on extensive areas or with liver impairment. |
Loading safety data…
| Lactation Rating | L3 |
| Teratogenic Risk | Topical corticosteroids like PSORCON (diflorasone diacetate) are assigned Pregnancy Category C. Systemic absorption is minimal with topical application, but extensive use, large areas, or occlusive dressings may increase absorption. In animal reproduction studies, corticosteroids have shown teratogenic effects (cleft palate, skeletal abnormalities) at relatively low doses. There are no adequate and well-controlled studies in pregnant women. Therefore, PSORCON should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk based on animal data; avoid if possible. Second and third trimesters: Use with caution, limit to small areas, short duration, and avoid occlusive dressings. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression (fatigue, hypotension, hyponatremia) if large areas are treated or occlusive dressings used. Monitor for fetal growth restriction if prolonged use. Assess for skin atrophy, striae, or secondary infection. No specific fetal monitoring is required with brief, limited use. |
| Fertility Effects | No human studies on fertility effects. In animal studies, corticosteroids may impair fertility (e.g., altered estrous cycles, implantation failure) at high systemic doses. Topical use with minimal absorption is unlikely to significantly affect fertility. |
| Clinical Pearls | PSORCON (diflorasone diacetate) is a high-potency topical corticosteroid. Use limited to 2 weeks continuous therapy on face, groin, or axillae. Avoid occlusive dressings unless directed. Systemic absorption can occur with extensive use, especially in children or on thin skin areas. |
| Patient Advice | Apply a thin layer to affected areas only; do not use on healthy skin. · Wash hands after application unless treating hands. · Do not cover the treated area with bandages or wraps unless told to. · Avoid contact with eyes, mouth, and open wounds. · Do not use for more than 2 weeks unless prescribed; report worsening or no improvement. · Avoid stopping abruptly; taper if used long-term. · Inform doctor if pregnant, breastfeeding, or planning to become pregnant. |